Despite long-term viral suppression with antiretroviral therapy (ART), HIV persists in reservoirs and sanctuary sites. Lifelong therapy is therefore necessary, leading to problems of compliance, toxicity, and cost. Over the last few years, important advances have been made in our understanding of the composition and the maintenance mechanisms of the HIV reservoir. Although complete viral eradication is currently out of reach, a growing number of scientists think that a "functional" cure is achievable. This situation would combine no disease progression, no virus transmission, and a life expectancy close to uninfected individuals in the absence of ART. At acute HIV infection, ART increases the frequency of sustained viremia control after its discontinuation, compared with the natural history of untreated disease. For patients at the chronic stage of HIV infection, ART alone is insuffi cient to clear viral reservoirs and new molecules intended to purge this reservoir or gene therapy approaches are warranted. This search for a cure needs innovation, audaciousness, and coordination. It also needs political, institutional, and private commitments for funding, which by now are severely lacking.
M
ajor therapeutic advances have been accomplished over the last 16 years with the discovery of potent antiretroviral therapy (ART), allowing HIV-infected patients to have longer and better lives. These treatments have also been constantly improved in order to reduce pill burden and side effects. However, they are all blocking HIV replication but do not prevent HIV persistence in the body. Consequently, lifelong ART is necessary; each time the drugs are stopped, the infection rekindles. This has been attributed to the early constitution, at acute infection, of viral reservoirs that are not infl uenced by ART. 1 Despite these improvements, the chance of a person infected with HIV reaching the age of 70 remains half that observed for uninfected controls in developed countries with high standards of care. 2 Successfully treated patients also experience an increased risk of cardiovascular diseases, neurocognitive defects, malignancies, and frailty. [3] [4] [5] It remains controversial whether this is a result of ART toxicity, slowly progressive HIV infection, persistent infl ammation, or a combination of these different factors. 6 Another "limit" of ART is its worldwide access. It is estimated that more than 7,000 new cases of HIV infection occur daily for a total of 33 million people living with HIV. Two-thirds of the cases reside in poor resource countries, where ART coverage is less than 40% according to the most restrictive guidelines. 2 Even in developed countries, ART access is a problem for those who are uninsured and an important fi nancial burden for social security systems. Therefore, the search for an HIV cure is urgent now more than ever. A sterilizing cure, where HIV genetic material can no longer be detected in an infected host, currently appears out of reach. 7 A "functional" cure looks more achievable. In this situation, even if HIV genetic material can still be in asymptomatic patients. 7 These cells do not progress to complete viral replication unless they are activated, and their stability and long half-lives are the major obstacles to HIV eradication. On the contrary, few data are available on other types of cells that could also contribute to the reservoir. In particular, the participation of multipotent hematopoietic stem/precursor cells 13 and monocytesmacrophages 14, 15 has been suggested. Monocytes circulate in the blood for up to 3 days and then migrate to various tissues where they differentiate into macrophages and have a life span ranging from days to months. Contrary to what happens to CD4+ T cells, cell viability of macrophages is not affected by HIV. The size of the infected monocyte-macrophage pool is estimated to be rather small compared to the infected T cell pool. 14 However, these cells can carry a large variety of HIV strains and can spread infection to CD4+ T cells. It has also been shown that antiretroviral drugs are less effective in macrophages compared to lymphocytes. 16 Finally, it is unknown whether the mechanisms maintaining HIV latency in CD4+ T cells are exactly the same as in stem cells and monocytes-macrophages.
At the anatomic level, some body compartments act as reservoirs and/or sanctuary sites for HIV. This is particularly true for the central nervous system where ART diffusion is incomplete. It could explain the high prevalence of neurocognitive disorders found in aviremic, ART-treated patients. 17 Actually, there is compelling evidence that HIV infection is only slowed in the brain during effective ART and that systemic control of HIV replication does not uniformly control brain disease. 18 The lymphoid tissue as a whole is a well-recognized HIV reservoir for more than 10 years, 19 and this has been recently confi rmed in macaque models of HIV latency. 20 The gut-associated lymphoid tissue (GALT) is another major reservoir for HIV throughout the course of infection. Sampling these tissues in clinical trials, like most other anatomic reservoirs, is diffi cult in patients who are otherwise well on ART. Consequently, no data are currently available on the cellular pharmacology of antiretroviral drugs in intestinal cells.
OPTIMIZATION OF ANTIRETROVIRAL THERAPY
The discrepancy of what is observed in plasma or in the systemic circulation compared to what detected in some tissues, patients do not experience clinical and immunological disease progression, do not transmit HIV, and have life expectancy similar to uninfected individuals in the absence of continued treatment. A similar situation exists naturally in the so-called elite controllers but concerns less than 1% of HIV-infected individuals. 1 In this article, I will briefl y review the reasons for HIV persistence and detail the strategies that are ready to be tested for an HIV infection cure.
HIV PERSISTENCE IN TREATED PATIENTS
Following the initiation of ART, a dramatic decrease of plasma viremia is observed, reaching undetectable clinical levels (<50 copies/mL) within a few weeks or months. 8 In fact, this decrease occurs in different phases, and viremia fi nally stabilizes around 1-5 copies/mL in most individuals. Despite this prolonged suppression of plasma viremia with ART, HIV replication rebounds each time therapy is stopped, even after more than 10 years of successful suppression. In fact, it was demonstrated in the late 1990s that a pool of resting latently infected T cells was established early after infection, which is maintained despite ART. 9 Consequently, HIV always induces a persistent infection, both at the cellular level and in anatomic compartments. HIV persistence therefore combines mechanisms acting at the cell level and others at the body level.
At the cellular level, integrated proviruses can be durably, yet reversibly, repressed by a combination of mechanisms. 10 Several groups have progressively deciphered some of these mechanisms in resting CD4+ T cells, demonstrating that HIV latency is an unstable state amenable to therapeutic attack. 11, 12 Most mechanisms maintaining HIV latency operate at the transcriptional level. Hypoacetylation of histones correlates with transcription repression, although histone methylation can be associated with both activation and silencing. HIV-1 expression is also strongly dependent on host cell transcription factors like NF-κB, NFAT (nuclear factor of activated T cells), and the positive transcription elongation factor b (P-TEFb)-cyclin complex. Finally, posttranscriptional mechanisms of regulation may also pose a barrier to provirus expression, like the RNA interference (RNAi) pathway. This reservoir of latently infected CD4+ T cells has been estimated to comprise 10 6 -10 7 cells happens in tissues has been particularly highlighted in intensifi cation trials. All these trials, testing the addition of a new antiretroviral drug in patients already suppressed with ART, failed to show any effect on the low levels of viremia between 1 and 50 copies/mL. 21 Therefore, they concluded that current ART was potent enough for totally blocking HIV replication. But when 2-long terminal repeat (2-LTR) circles were measured in circulating lymphocytes, a trial found 22 that they were transiently elevated in 29% of patients in the fi rst few weeks following raltegravir intensifi cation, compared to 5% of patients in the control group (P = .025). This transient increase in 2-LTR circles with raltegravir could only be explained by the presence of ongoing viral replication, and the observation that most increases in 2-LTR circles occurred in patients taking a protease inhibitor raised the possibility that these regimens are less potent than others. Finally, when gut biopsies were analyzed at different levels during another trial of raltegravir intensifi cation, ongoing productive infection was found in some patients in the terminal ileum. 23 Although there is still no defi nite answer as to whether ongoing viral replication persists in some patients during effective ART, or in some locations, this is of major importance in terms of a cure. If it were demonstrated that despite triple-drug combinations HIV could still replicate at a low rate in some compartments, then it would imply that the priority is to optimize ART before trying to eradicate HIV. In that way, a score for ART effectiveness in the central nervous system has been proposed. 24 The origin of persistent low-level HIV RNA during ART remains controversial. Some studies have shown that, in almost half of cases, residual viremia <50 copies/mL contains predominant plasma clones different from those detected in the circulating latently infected CD4+ T cell pool. 25 Other studies, also on a few number of cases, found that sequences were identical between these 2 compartments. 26 Recently, an interesting analysis showed that episomal sequences prior to treatment interruption were closely related to rebounding virus when ART was stopped, although proviral sequences were not. 27 These data support the fact that rebounding virus after ART cessation is derived from actively replicating virus and that a cryptic reservoir with active replication persists in patients on suppressive therapy. Another study did not fi nd a direct origin of rebounding plasma virus after ART cessation from the GALT, 28 arguing that other remote reservoirs still have to be characterized.
Consequently, if triple-drug combinations are not effi cient enough to stop HIV replication in all compartments, combinations with more than 3 drugs (mega-ART) should be considered.
ART AT ACUTE HIV INFECTION
Following HIV infection, the virus fi rst replicates in the mucosa, then is transported to draining lymph nodes, and fi nally disseminates throughout the body. The time between the initial infection and the fi rst detection of viral RNA in the plasma is referred to as the "eclipse phase." 29 It usually takes less than 5 to 7 days. HIV viremia then increases exponentially, with a peak at 21 to 28 days, followed by a slower decline. Finally, viremia stabilizes 3 to 6 months later, corresponding to the viral set point.
By the time of the peak of viremia, a signifi cant destruction of CD4+ T cells both in blood and in GALT has already occurred. CD4+ T cell numbers can later return to normal in blood but not in gut. 29 The GALT is, therefore, the fi rst abundant HIV reservoir just before the viremia peak and remains a major reservoir throughout the course of the disease. In addition to this reservoir of replicating virus, the pool of latently infected, resting CD4+ T cells is established at this time. Finally, an expansion of HIV-specifi c CD4+ T cells occurs in acute HIV infection, but these responses rapidly decline.
Therefore, it is estimated that following transmission of HIV there is a potential 5-to 10-day window of opportunity when a therapeutic intervention could be decisive or even eradicate virus-infected cells. 29 Conducting clinical trials at acute HIV infection has been a diffi cult task for several reasons. First, initial trials used zidovudine monotherapy that showed limited potency. 30 Then, it is particularly diffi cult to diagnose acute HIV infection early enough to include patients before they get more than 3 positive bands on the Western blot HIV test. Initial ELISA tests were less sensitive than current tests and were not systematically coupled with p24 antigen detection. The general practitioners who received the fi rst barely positive tests waited a few weeks for confi rmation, and the acute phase was over. This explains why trials and cohorts contained both real cases of acute HIV infection and cases of France at acute infection, 12% of the 223 cases who received an early therapy course kept viremia levels <500 copies/mL for a median period of 27 months after ART interruption. 31 Predictive factors for HIV control after therapeutic interruption comprised lower HIV DNA levels, 31 as was previously published. 33 Recently, Hocqueloux and colleagues identifi ed in 3 clinical centers 32 a series of 32 patients who received effective ART at acute infection, reaching undetectable viremia, followed by interruption. In 5 cases (15.6%), a sustained immuno-virological control was maintained for a mean duration of 77 months. These post-treatment controllers had received ART for a median period of 4.97 years and did not have the HLA class I B27 or B57 alleles of elite controllers. 32 One of these patients is depicted in Figure 1 . Plasma viremia not only never rebounded after ART cessation, but also was consistently below 1 copy/mL. Cell-associated HIV DNA was measured at 2 log copies/10 6 peripheral blood mononuclear cells (PBMC) 5 years after diagnosis, and then was consistently undetectable (<20 copies/10 6 PBMC). A rectal biopsy performed at 10 years showed undetectable HIV RNA levels, but cell-associated HIV DNA was quantifi ed at 3.5 log copies/10 6 rectal CD4+ T cells (Figure 1) .
early infection, which is a totally different situation. Finally, as acute HIV infection is frequently asymptomatic or exhibits nonspecifi c symptoms, trials tended to recruit the most severe cases. As a consequence, the literature on acute HIV infection consists predominantly of small nonrandomized studies, and fewer than 5 randomized trials have currently been published. 31 They do not give a fi nal answer to the potential long-term benefi t of a course of ART initiated at that time and subsequently discontinued, but they give important clues.
Regarding viral markers, early initiation of ART has been associated with a decrease in cell-associated HIV DNA levels more important than that noted when therapy is initiated during chronic infection. Concerning the possibility of prolonged benefi ts of early treatment followed by cessation, the results vary according to studies. 31 However, there is a trend that early treatment delays CD4 cell decline and increases the need to re-start ART. 31 More interesting is the fact that a course of ART initiated at acute infection followed by discontinuation could provide long-lasting virologic control in an increased proportion of patients compared to the course of natural history. 31, 32 In a multicenter, observational cohort of 1,089 patients enrolled in , and CD4+ T cell count (dashed line) are shown over a period of 12 years. Antiretroviral therapy (ART) with 2 HIV reverse transcriptase inhibitors plus 2 HIV protease inhibitors was administered at the time of acute HIV infection for 2 years followed by interruption. The fi rst dotted threshold at the bottom of the graph represents 1 copy of HIV RNA/mL, the second represents 20 copies/mL. A rectal biopsy was performed at 10 years of follow-up. The patient was diagnosed with acute HIV infection in March 1998 with only 2 positive bands on the Western blot; plasma viremia was at 5.6 log copies/mL, cell-associated HIV DNA at 4.6 log copies/10 6 PBMC with a CD4+ T cell count of 351 cells/mm 3 . Plasma viremia remained below 1 copy/mL after ART cessation, and cell-associated HIV DNA in PBMC was consistently undetectable after 5 years.
expression following the recruitment of histone deacetylases (HDAC) to the HIV LTR. 11 Many drugs that inhibit HDAC activity were confi rmed to induce HIV transcription in latently infected cell lines and in resting CD4+ T cells isolated from patients. 12 Actually, among the 4 classes of HDAC, only class I, including HDAC1, HDAC2, and HDAC2, occupies the HIV LTR. Initial studies addressing the potential role of HDAC inhibition in clearing HIV used valproic acid, but the results were disappointing. SAHA, or vorinostat, is a more potent HDAC1 inhibitor already approved for the treatment of cutaneous T cell lymphoma that will be next to be tested to accelerate the decay of the latent reservoir.
A number of other HDAC inhibitors are being actively developed as anticancer agents. One of the main barriers toward their use against HIV could be their toxicity, which is less a concern in cancer patients without other alternatives. On the contrary, in virally suppressed patients on ART with good prognosis, the risk-benefi t ratio has to be low.
In addition to HDAC inhibition, other pathways involved in proviral latency are identifi ed with their potential pharmacologic approaches. 39, 40 The protein kinase C (PKC) signaling pathway plays an important role. Several pharmacologic PKC agonists, including a jatrophane diterpene (SJ23B), bryostatin, and prostratin, induce proviral expression effi ciently in latently infected CD4+ T cells. 37 Prostratin is a naturally occurring non-tumorproducing phorbol ester that was initially derived from the bark of certain trees in the South Pacifi c but can now be synthesized. Prostratin also downregulates HIV-1 receptors, which has the additional advantage of decreasing the risk of propagating infection. 40 Interleukin-7 (IL-7) can reactivate HIV-1 in latently infected cells through the induction of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. However, IL-7 is also involved in the homeostatic proliferation of the HIV reservoir. 41 IL-7 induces Bcl-2, a key anti-apoptotic protein ensuring survival of proliferated cells. Anti-Bcl2 products are being developed for cancer therapy that might help by not expanding the reservoir with IL-7. 37 Finally, other agents as hexamethylene bisacetamide (HMBA) have been identifi ed for releasing P-TEFb and enhance HIV proviral expression. 37 There are some uncertainties with the use of these antilatency agents for purging the HIV reservoir. This patient did not have HLA B27 or B57 alleles of protection or a delta 32 deletion on the CCR5 coding gene.
Other studies have confi rmed that initiating ART at acute infection can signifi cantly reduce the reservoir size compared to starting at the chronic stage of the disease. In the PINT study, 34 both total and integrated HIV DNA levels in PBMC were signifi cantly lower at 52 weeks in the acutely infected group. However, the number of drugs to use in this situation remains unclear. Despite recent data showing high effi cacy of a mega-ART combination of 5 drugs 35 in both blood and gut cells, a small randomized study did not fi nd any advantage in terms of viral control, proviral DNA decrease, or immune reconstitution of 5 versus 3 drugs. 36 Other trials are currently ongoing, such as the French ANRS (Agency for AIDS Research) study (ClinicalTrials. gov Identifi er: NCT01033760), comparing standard ART with mega-ART including new drug classes (an integrase inhibitor plus a CCR5 inhibitor) at acute HIV infection.
Nevertheless, there is already a strong case for interventions at this stage of disease with the potential of achieving virologic control despite treatment cessation more frequently than in spontaneous elite controllers.
PURGING THE HIV RESERVOIR
In this approach, drugs are added to ART for reactivation of the latent HIV reservoir in order to deplete it. A central assumption of this strategy is that the disruption of HIV latency in the reservoirs will make the infected cells vulnerable to elimination by host immune responses and viral cytopathic effects. 37 Immune activation has historically been the fi rst purging intervention tested. 38 Activation of T cells was supposed to reverse the blocks preventing transcription of the HIV genome, leading to viral production and clearance of these activated cells due to their shorter half-life. Unfortunately, all the attempts using OKT3 antibodies, interleukin-2, and gamma-interferon were unsuccessful and sometimes toxic. 38 With a better understanding of the mechanisms controlling HIV latency, more targeted strategies emerged. Deacetylation of histones at the nucleosome of the HIV long terminal repeat (LTR) has been demonstrated to constitute a barrier to viral of genetically engineered HIV resistant or HIVtargeted cells and a potential to provide stable control or eradication of HIV. 46 The concept of intracellular immunization uses gene-based reagents capable of inhibiting viral replication, increasing expression of host restriction factors, or inhibiting HIV receptors expression. Successful replacement of a patient immune system by gene-modifi ed HIV protected cells may have the potential to minimize viral loads as well as reduce reservoirs of infected and latently infected cells. 46 In 2009, the report of the Berlin patient who developed acute myeloid leukemia and was transplanted with hematopoietic stem cells (HSCs) from a human leukocyte antigen-matched, homozygous CCR5 delta 32 donor changed our views on HIV eradication. 47 CCR5 is a co-receptor critical for HIV entry into cells. A small fraction of people carry a 32-base-pair deletion in the CCR5 gene. Those who are heterozygous for CCR5 delta 32 have delayed disease progression after they acquire HIV, whereas homozygotes rarely acquire HIV. 48 ART was discontinued the day before the transplant in the Berlin patient. Twenty months later, HIV could not be detected in any of the patient tissues examined. At the end of 2010, the situation was confi rmed, leading the authors to fi nally use the word "cure" after nearly 4 years of follow-up. 49 This important observation inspired several groups to pursue CCR5-targeted gene therapy. A fi rst set of experiments came from a mouse model. 50 CD34+ hematopoietic stem/progenitor cells, a population enriched in HSCs, were obtained from umbilical cord blood and stimulated to divide. The cells were nucleofected with plasmids expressing CCR5-specific zinc-finger nucleases. These nucleases act as molecular scissors. After specifi c binding of a pair of zinc-fi nger nucleases to the CCR5 gene, a double-stranded DNA break is introduced and then repaired by pathways that include error-prone nonhomologous end-joining. This can create a permanent gene disruption that is passed to daughter cells in the absence of persistent transgene expression. The end result is the functional disruption of the CCR5 gene. A mean of 17% of the cells were successfully modifi ed, 5% to 7% of which were estimated to be homozygous CCR5-. Modifi ed or unmodifi ed CD34+ cells were then transplanted into nonobese diabetic/severe combined immunodefi cient/interleukin 2rγ null mice, a model known to support
The fi rst one is their ability to reach all kinds of cells of the reservoir in their different nature and location. It might be necessary to sequence or combine several antilatency agents to obtain the purge. Second, the ART regimen used during the purge must also be able to reach effi ciently each body compartment, such as the brain and the gut. HDAC inhibitors are lipophilic and should easily reach the brain; but if ART is not totally effective at this level, this could cause more harm than good. 42 It is unknown whether a threshold exists, below which we can drive the HIV reservoir so that the body will be able to control it. The recent observation 43 of a patient with undetectable HIV DNA both in blood and in tissue who experienced viremia rebound after ART cessation tends to show that such a limit does not exist. If it is proven that one remaining latently infected cell is suffi cient to reignite a whole infection, purging approaches will have to be complemented by other interventions in a cancer model strategy tracking residual HIV disease. 2 One of these complements could be to target specifi cally HIV-infected cells by immunotoxins. 44 Because resting latently HIV-infected cells do not express specifi c markers or HIV proteins, they are invisible for immunotoxins and have to be activated fi rst. The fi rst attempt with immunotoxins was a phase I clinical trial before the ART era. 45 It showed no antiviral effect and hepatic dose-limiting toxicity. New immunotoxins have now been designed, including the Pseudomonas aeruginosa exotoxin A and a targeting moiety directed against the highly conserved CD4 binding site on gp120, 44, 45 which caused no hepatotoxicity in rhesus macaques. These toxins are ready to enter phase I trials where they will be administered during short periods of 1 or 2 weeks based on cancer protocols. 45 Another complement to purging approaches would be a therapeutic vaccine able to control the few remaining infected cells, but this faces the same diffi culties as preventive HIV vaccine development.
GENE THERAPY
Human stem cell-based therapeutic strategies for treating HIV infection have recently undergone a major focus of investigation. Hematopoietic stem/progenitor cells (HSC) are capable of selfrenewal and differentiation into all hematopoietic lineages. An HSC-based gene therapy approach would offer continuous, long-term production loads. To satisfy ethical requirements, the design study included infusion of unmanipulated hematopoietic progenitor cells in order to provide standard-of-care treatment. Despite probable competition for engraftment, all patients engrafted at 11 days post transplant. Median follow-up was 18 months, but the gene marking in peripheral blood mononuclear cells remained low at 0.02% to 0.32% of the cells during this period. No anti-HIV benefi t was demonstrated, although the percentage of gene-marked cells for a benefi t is unknown. It is also possible that a selection factor, such as ART interruption, would have been a useful component of this approach.
It is important to note that even if a competent immune system could be rebuilt, a functional cure would not be achieved if viremia and/or infl ammation remained detectable. Although HIV can directly kill cells, most cells in an HIV-infected patient die as a consequence of indirect viral effects. A strategy that would not correct the generalized immune activation observed during HIV infection would probably not halt disease progression.
Another prospect of gene therapy is the design of LTR-specifi c recombinase (Tre recombinase) able to remove proviral HIV DNA in infected cells. 56 Before it will become a reality in the clinic, various aspects of specifi city, cytotoxicity, and mode of delivery have to be resolved.
A last use of gene therapy consists in engineering immune cells to directly target and kill HIV. 46 Although the immune system is incapable naturally of eradicating HIV infection, the use of a HSC-based approach would allow multilineage hematopoietic development and the direction of several arms of the immune system against HIV. In particular, both neutralizing antibodies and cytotoxic T lymphocytes (CTLs) targeting HIV could be produced. Although the current preclinical development of this approach is ongoing, it represents a potential means to increase the quality and quantity of the specifi c anti-HIV immune response.
WHAT IS NEEDED TO MOVE FORWARD
The development of new approaches for a HIV infection cure needs innovation, commitment, and coordination. More basic research is needed to understand all the mechanisms involved in HIV latency and the different types of reservoirs present in a given patient. multilineage human hematopoiesis. As expected, mice engrafted with unmodifi ed stem cells and subsequently challenged with CCR5-tropic HIV showed high levels of viremia and loss of peripheral and tissue-based human T cells. Remarkably, in animals repopulated with CCR5-disrupted HSCs, virus levels were lower and CD4+ T cells were not depleted, either in the peripheral blood or in the lymphoid tissues. Actually, the frequency of cells containing evidence of CCR5 disruption increased to >80% in the peripheral blood and to >40% in multiple tissues by week 12 of infection. The observation of almost complete replacement of human T cells in the intestines of the infected mice with CCR5-cells is consistent with this tissue harboring the majority of the body CD4+CCR5+ effector memory cells. This result raises the intriguing possibility that HIV-infected individuals might be functionally cured with a one-time infusion of autologous, gene-modifi ed HSCs.
Recently, the preliminary results of the fi rst 2 clinical studies testing zinc-finger nucleases mediated CCR5 disruption (ZN-M-R5-D) were reported. 51, 52 Overall, 15 patients were analyzed. Autologous R5-disrupted T cells were expanded ex vivo and several billions re-injected to patients. Infusions were safe and well-tolerated; successful engraftment was observed in all but one patient, with homing to gut mucosa and persistence of the circulating modifi ed cells. The same kind of ZN-M-R5-D is also tried on stem cells 53 and currently tested in mice models. It is interesting to note that in these experiments, the zinc fi nger nuclease technology was not only able to knock out the CCR5 gene, but also allowed site-specifi c gene addition through homologous recombination. This has been demonstrated by using a gene coding for the green fl uorescent protein but, in the future, will use cellular genes with a HIV protective effect.
However, single anti-HIV gene therapy will likely fail due to the development of escape mutations in the virus that confer resistance to the therapy. 46 Effective gene therapy will likely require a combination of multiple reagents directed against HIV. In this way, there are also attempts to knock out CXCR4 expression. 54 Finally, in a recent clinical study, a triple combination of an anti tat/rev shRNA, a TAR decoy, and an anti-CCR5 ribozyme was introduced in AIDS lymphoma patients through HSC transplant. 55 All patients were maintained on ART, with undetectable viral barriers will be important for translational research. However, with a coordinated approach including scientists, governmental agencies, drug companies, and patients, it is possible to gain a lot of time. There are already promising interventions that should advance toward human testing (Figure 2) .
Finally, the ultimate need is a real commitment from investors. Money for HIV cure research is scarce, especially for risky new ideas that might not pan out. In developed countries, the market for antiretroviral drugs is relatively closed as most patients needing ART already receive it. In developing countries, there is a potential market, but most patients cannot afford therapy costs. Consequently, drug companies prefer massively funding the marketing of their current antiretrovirals and satisfying their stockholders rather than investing in putative strategies. Regarding governmental agencies, they have been iced by the failure of vaccine research, despite the large amount of money they poured in. With the economic crisis, they shy away from another initiative that could not be a success.
Better animal models of HIV persistence and reservoirs are necessary to guide clinical trial designs. Important advances have already been achieved over the last few years with SIV in macaque models or HIV in the BLT (bone marrow-liver-thymus) mouse model. 57 New biological tools have to be developed to quantify residual HIV disease during eradication trials. Quantifi cation of replication-competent virus is time consuming and needs huge quantities of blood. Conversely, cell-associated HIV DNA quantifi cation certainly overestimates the number of remaining viral genomes able to rekindle infection. Furthermore, there is a need to access lymphoid tissues and diverse anatomic compartments with less invasive methods than currently available. The ultimate endpoint in clinical trials will, however, remain ART interruption.
The effi cacy of ART and the quality of life it provides together with an increased life expectancy imply that eradication approaches have to be safe and tolerable. This also means that regulatory 
